(GLSI) – Business Wire
-
Greenwich LifeSciences Provides Year End Update
-
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023
-
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
-
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
-
Greenwich LifeSciences Provides Financing Strategy & Corporate Update
-
Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed
-
Greenwich LifeSciences Announces Suspension of Share Repurchase Program
-
Greenwich LifeSciences to Resume Stock Repurchase Program
-
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
-
Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences
-
Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
-
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting
-
Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
-
Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
-
Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year
-
Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
-
Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
-
Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
-
Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
-
Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
-
Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
-
Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference
-
Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
-
Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
-
Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts
-
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
-
Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference
-
Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
-
Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
-
Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
-
Greenwich LifeSciences to Participate in Citi’s 16th Annual Biopharma Virtual Conference
-
Greenwich LifeSciences Set to Join Russell 2000® Index
-
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated
-
Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization
-
Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
-
REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival
-
Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recu
-
Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up
-
Greenwich LifeSciences CEO to Participate on Cancer Panel and to Present at Benzinga Biotech Conference
-
Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting
-
Greenwich LifeSciences CEO to be Interviewed Live on Benzinga’s Power Hour
-
Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer
-
Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and BIO-Europe Spring Conferences
-
Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming Major Cancer Conference
-
Greenwich LifeSciences Announces Exercise and Closing of Underwriter’s Over-Allotment Option
-
Greenwich LifeSciences CEO Interview to Air on Bloomberg International on the RedChip Money Report
-
Greenwich LifeSciences to Present at B. Riley Securities and BIO CEO & Investor Conferences
-
Greenwich LifeSciences to Participate in Multiple Virtual Investor Conferences During 2021 JP Morgan Healthcare Week
-
Greenwich LifeSciences’ LD Micro Presentation Replay Now Available
-
Greenwich LifeSciences to Ring Nasdaq Opening Bell on December 28
Back to GLSI Stock Lookup
